Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancerShunichi Sugawara, Kazuhiko Nakagawa, J.-S. Lee et al.|Annals of Oncology|2021Cited by 202
First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the <scp>ONO</scp>‐4538‐52/<scp>TASUKI</scp>‐52 randomized controlled trialHye Ryun Kim, Kazuhiko Nakagawa, Shunichi Sugawara et al.|Cancer Medicine|2023Cited by 26
Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE)Akito Hata, Tomohide Tamura, Yoshimasa Shiraishi et al.|Oncology and Therapy|2022Cited by 17
Multicenter, placebo‐controlled, double‐blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy‐induced nausea and vomiting in patients receiving highly emetogenic chemotherapyShunichi Sugawara, Tomohide Tamura, Naoki Inui et al.|Cancer|2019Cited by 16
LBA54 Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLCJS Lee, Kazuhiko Nakagawa, Shunichi Sugawara et al.|Annals of Oncology|2020Cited by 14